CAMBRIDGE, Mass.— City Therapeutics, a private biopharmaceutical company focused on RNA interference (RNAi)-based therapeutics, has announced key additions to its executive team and board of directors as it prepares to advance its first clinical program by year-end.
The company has appointed Baisong Mei, M.D., Ph.D., as Chief Medical Officer, and Anna O’Driscoll as Chief Human Resources Officer. Additionally, Sara Nochur, Ph.D., has joined the board of directors as an independent member.
“With our RNAi platform and pipeline progressing rapidly, now is the right time to bolster our leadership team and board with proven experts,” said Andy Orth, CEO of City Therapeutics. “We’re excited to welcome Baisong, Anna, and Sara as we enter this next phase of growth.”
Dr. Mei brings over 25 years of biopharmaceutical experience to his new role, including leadership in the clinical development of several approved therapies such as ALPROLIX®, ELOCTATE®, and ALTUVIIIO®. Most recently, he served as Executive Vice President and Chief Medical Officer at Editas Medicine and previously held senior roles at Sanofi, Biogen, and Bayer.
Ms. O’Driscoll joins City Therapeutics with extensive human resources and leadership development expertise, having served as Chief People and Communications Officer at
Cellarity and held senior HR roles at Alnylam Pharmaceuticals, Shire, and Johnson & Johnson. She will oversee talent strategy, organizational development, and internal culture as the company scales.
Dr. Nochur, a regulatory affairs veteran with 35 years of experience, adds strategic oversight to the board. She previously served as Chief Regulatory Officer and later Chief Diversity, Equity and Inclusion Officer at Alnylam Pharmaceuticals, where she led global regulatory approvals for multiple RNAi therapeutics, including ONPATTRO® and GIVLAARI®.
These appointments come as City Therapeutics positions itself to bring its next-generation RNAi therapies to clinical trials and expand its pipeline of RNA-based medicines.
